BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35574900)

  • 1. In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis.
    Kidd SG; Bogaard M; Carm KT; Bakken AC; Maltau AMV; Løvf M; Lothe RA; Axcrona K; Axcrona U; Skotheim RI
    Mol Oncol; 2022 Aug; 16(15):2810-2822. PubMed ID: 35574900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.
    Huang KC; Dolph M; Donnelly B; Bismar TA
    Clin Transl Oncol; 2014 Nov; 16(11):973-9. PubMed ID: 24796295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
    Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
    Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
    Lippolis G; Edsjö A; Stenman UH; Bjartell A
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
    Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
    Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
    Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.
    Szász AM; Majoros A; Rosen P; Srivastava S; Dobi A; Szendrői A; Kulka J; Nyirády P
    Int Urol Nephrol; 2013 Jun; 45(3):727-33. PubMed ID: 23686669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
    Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
    J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of ERG and PTEN status in prostate cancer patients underwent radical prostatectomy.
    Fragkoulis C; Glykas I; Tzelves L; Stamatakos PV; Papadopoulos G; Stathouros G; Dellis A; Ntoumas K; Kostopoulou A; Deliveliotis C; Papatsoris A
    Arch Ital Urol Androl; 2022 Dec; 94(4):390-395. PubMed ID: 36576468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.
    Rye MB; Bertilsson H; Drabløs F; Angelsen A; Bathen TF; Tessem MB
    BMC Med Genomics; 2014 Aug; 7():50. PubMed ID: 25115192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERG upregulation and related ETS transcription factors in prostate cancer.
    Rostad K; Mannelqvist M; Halvorsen OJ; Oyan AM; Bø TH; Stordrange L; Olsen S; Haukaas SA; Lin B; Hood L; Jonassen I; Akslen LA; Kalland KH
    Int J Oncol; 2007 Jan; 30(1):19-32. PubMed ID: 17143509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
    Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.
    Raymundo EM; Diwa MH; Lapitan MC; Plaza AB; Sevilleja JE; Srivastava S; Sesterhenn IA
    Prostate; 2014 Aug; 74(11):1079-85. PubMed ID: 24909781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.